

# Frdric Perros

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1307351/frederic-perros-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112  
papers

7,789  
citations

44  
h-index

87  
g-index

146  
ext. papers

9,142  
ext. citations

8.5  
avg, IF

5.53  
L-index

#	Paper	IF	Citations
112	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	5
111	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , <b>2021</b> , 159, 1197-1207	5.3	5
110	Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. <i>Cells</i> , <b>2021</b> , 10,	7.9	7
109	Central Role of Dendritic Cells in Pulmonary Arterial Hypertension in Human and Mice. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
108	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 2474-2488	9.9	4
107	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. <i>Communications Biology</i> , <b>2021</b> , 4, 1002	6.7	
106	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1306-1315	4.7	0
105	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension.. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	1
104	Pulmonary capillary haemangiomatosis: a distinct entity?. <i>European Respiratory Review</i> , <b>2020</b> , 29,	9.8	9
103	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 843-852	10.2	4
102	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	11
101	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020907884	2.7	1
100	Familial pulmonary arterial hypertension by heterozygous loss of function. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	23
99	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension <b>2020</b> , 63-70		1
98	In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. <i>Respiratory Research</i> , <b>2020</b> , 21, 186	7.3	10
97	Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2020</b> , 319, L627-L640	5.8	10
96	Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cell-Dependent Endothelial Cell Apoptosis. <i>Hypertension</i> , <b>2020</b> , 76, 985-996	8.5	6

95	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 148-157	10.2	29
94	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2020</b> , 63, 118-131	5.7	11
93	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 1159-1175	5.8	14
92	The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	11
91	Response by Mendes-Ferreira et al to Letter Regarding Article, "Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension". <i>Circulation</i> , <b>2019</b> , 140, e288-e289	16.7	50
90	BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1187-1188	10.2	0
89	Characterization of -Mutated Rat, a Novel Model of Pulmonary Hypertension. <i>Circulation Research</i> , <b>2019</b> , 125, 678-695	15.7	42
88	Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	11
87	Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 932-948	16.7	50
86	The integrated stress response system in cardiovascular disease. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 920-928	9.8	11
85	Ca handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2018</b> , 118, 208-224	5.8	34
84	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2018</b> , 137, 2371-2389	16.7	46
83	Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 1164-1177	1.9	36
82	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , <b>2018</b> , 114, 880-893	9.9	31
81	Respiratory effects of trichloroethylene. <i>Respiratory Medicine</i> , <b>2018</b> , 134, 47-53	4.6	22
80	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 647-655	5.8	31
79	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , <b>2018</b> , 40, 790-794	2.3	3
78	Identity crisis in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217746054	2.7	4

77	Pulmonary hypertension associated with neurofibromatosis type 1. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	18
76	Gut-Lung Connection in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2017</b> , 56, 402-405	5.7	25
75	Use of $\beta$ blockers in Pulmonary Hypertension. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	41
74	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. <i>ACS Nano</i> , <b>2017</b> , 11, 112-125	16.7	279
73	Early Development of Right Ventricular Ischemic Lesions in a Novel Large Animal Model of Acute Right Heart Failure in Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 876-886	3.3	12
72	T-type Ca channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2017</b> , 1864, 1631-1641	4.9	11
71	Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. <i>Respirology</i> , <b>2017</b> , 22, 157-164	3.6	33
70	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 583-595	10.2	95
69	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. <i>Oncotarget</i> , <b>2017</b> , 8, 52995-53016	3.3	30
68	BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2016</b> , 468, 1969-1983	4.6	12
67	MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 72-82	4.2	25
66	$\beta$ blockers in pulmonary arterial hypertension: generation might matter. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 682-4	13.6	3
65	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2016</b> , 133, 1371-85	16.7	98
64	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , <b>2016</b> , 133, e592-3	16.7	4
63	Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series). <i>Pulmonary Circulation</i> , <b>2016</b> , 6, 448-464	2.7	31
62	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1518-34	13.6	134
61	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 1273-1285	10.2	61
60	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. <i>Proteomics</i> , <b>2016</b> , 16, 2637-2649	4.8	18

59	Endothelial-to-mesenchymal transition in pulmonary hypertension. <i>Circulation</i> , <b>2015</b> , 131, 1006-18	16.7	320
58	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. <i>Circulation</i> , <b>2015</b> , 132, 834-47	16.7	80
57	Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 457-67	5.8	26
56	Potassium channels in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1167-77	13.6	49
55	miR-223 reverses experimental pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , <b>2015</b> , 309, C363-72	5.4	91
54	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1721-31	13.6	55
53	Response. <i>Chest</i> , <b>2015</b> , 148, e132-e133	5.3	
52	Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. <i>Respiratory Research</i> , <b>2015</b> , 16, 114	7.3	16
51	A simple method to assess in vivo proliferation in lung vasculature with EdU: the case of MMC-induced PVOD in rat. <i>Analytical Cellular Pathology</i> , <b>2015</b> , 2015, 326385	3.4	4
50	S6 The profiles of JMJD3, UTX and H3K27me3 expression in pulmonary vasculature in rat MCT model of PAH and human iPAH: implications for pulmonary arterial hypertension. <i>Thorax</i> , <b>2015</b> , 70, A7-A8 <sup>7.3</sup>		
49	T-helper 17 cell polarization in pulmonary arterial hypertension. <i>Chest</i> , <b>2015</b> , 147, 1610-1620	5.3	52
48	Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 668-80	15.1	101
47	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 356-71	5.8	116
46	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , <b>2014</b> , 15, 65	7.3	34
45	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. <i>Circulation</i> , <b>2014</b> , 129, 1332-40	16.7	110
44	Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 451, 8-14	3.4	47
43	CXCL13 in tertiary lymphoid tissues: sites of production are different from sites of functional localization. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 369-70	10.2	2
42	Evidence for the involvement of type I interferon in pulmonary arterial hypertension. <i>Circulation Research</i> , <b>2014</b> , 114, 677-88	15.7	97

41	Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1251-6	8.8	39
40	Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. <i>PLoS ONE</i> , <b>2014</b> , 9, e109291	3.7	20
39	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , <b>2013</b> , 8, 97	4.2	168
38	A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 756-9	10.2	37
37	The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2013</b> , 44, 31-8	12.3	73
36	S142 The role of H3K27 methylation in vascular endothelial cell proliferation and function: implications for pulmonary arterial hypertension. <i>Thorax</i> , <b>2013</b> , 68, A73.1-A73	7.3	
35	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 189-96	10.2	42
34	Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2013</b> , 34, 714-24	3.9	45
33	Nuclear factor $\kappa$ B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. <i>PLoS ONE</i> , <b>2013</b> , 8, e75415	3.7	62
32	The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. <i>PLoS ONE</i> , <b>2013</b> , 8, e77073	3.7	9
31	Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 780-9	10.2	244
30	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 895-904	13.6	84
29	Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 185, 311-21	10.2	194
28	Tertiary lymphoid organs in infection and autoimmunity. <i>Trends in Immunology</i> , <b>2012</b> , 33, 297-305	14.4	241
27	A study of magnesium deficiency in human and experimental pulmonary hypertension. <i>Magnesium Research</i> , <b>2012</b> , 25, 21-7	1.7	2
26	Pulmonary arterial hypertension in patients treated by dasatinib. <i>Circulation</i> , <b>2012</b> , 125, 2128-37	16.7	448
25	Circulating fibrocytes and pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 210-23.6	3.6	5
24	A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 666-76	10.2	68

23	Inflammation in pulmonary arterial hypertension. <i>Chest</i> , <b>2012</b> , 141, 210-221	5.3	279
22	Inflammation in Pulmonary Arterial Hypertension <b>2012</b> , 213-229		1
21	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. <i>Respiratory Research</i> , <b>2011</b> , 12, 119	7.3	64
20	TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. <i>Respiratory Research</i> , <b>2011</b> , 12, 125	7.3	60
19	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 813-22	13.6	75
18	C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 116-23	10.2	147
17	Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2011</b> , 37, 1392-9	13.6	78
16	Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 1209-11	13.6	23
15	S154 Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension?. <i>Thorax</i> , <b>2010</b> , 65, A70-A70	7.3	2
14	S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression. <i>Thorax</i> , <b>2010</b> , 65, A68-A69	7.3	
13	P29 Endothelial cell NF-kB activation is increased in human idiopathic PAH. <i>Thorax</i> , <b>2010</b> , 65, A88-A89	7.3	
12	Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 731-9	13.6	2
11	House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. <i>Nature Medicine</i> , <b>2009</b> , 15, 410-6	50.5	835
10	Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 64, 995-1002	9.3	112
9	Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. <i>Vascular Pharmacology</i> , <b>2008</b> , 49, 113-8	5.9	90
8	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 81-8	10.2	336
7	Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. <i>Respiration</i> , <b>2008</b> , 75, 253-6	3.7	7
6	Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 937-43	13.6	124

5	Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2007</b> , 29, 462-8	13.6	137
4	Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 1041-7	10.2	173
3	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. <i>Human Pathology</i> , <b>2007</b> , 38, 893-902	3.7	238
2	Current insights on the pathogenesis of pulmonary arterial hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2005</b> , 26, 355-64	3.9	33
1	Inflammation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2003</b> , 22, 358-63	13.6	473